<i>MDM2/MDM4</i> amplification and <i>CDKN2A</i> deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy.
Taylor E. Arnoff, Wafik S. El‐Deiry
Abstract
alterations may benefit from combinations of targeted inhibitors of MDM2/4 and CDK4/6, as well as immunotherapy.
Topics & Concepts
CDKN2AMelanomaCancer researchMedicineMdm2ImmunotherapyMetastasisCancerBiomarkerOncologyInternal medicineBiologyApoptosisBiochemistryCancer Genomics and DiagnosticsCAR-T cell therapy researchCancer Immunotherapy and Biomarkers